Trial Profile
Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of COZAAR XQ in Usual Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2022
Price :
$35
*
At a glance
- Drugs Amlodipine/losartan (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 16 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 28 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Jun 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.